Preferences and actual chemotherapy decision-making in the greater plains collaborative breast cancer study

Berger, Ann M.; Buzalko, Russell J.; Kupzyk, Kevin; Gardner, Bret J.; Djalilova, Dilorom M.; Otte, Julie L.

doi:10.1080/0284186x.2017.1374555

Cited by 24 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knowing patients' treatment preference is paramount in patient care. There is a renewed interest in implementation of a shared decision-making process between patients and healthcare, ultimately enhancing treatment quality [20,21]. Notably, it has been proven that patients with BC (16%) value the efficacy less than the sideeffects [22] and are willing to make trade-offs between side-effects and different regimens [23].…”

Section: Discussionmentioning

confidence: 99%

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

et al. 2020

View full text Add to dashboard Cite

Background: The objective of the IMPROVE study was patients' preference for either endocrine-based therapy or combined chemo-and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. Methods: In this randomized, cross-over phase IV study, 77 patients were recruited in 26 sites in Germany. Patients were randomized 1:1 to receive either capecitabine plus bevacizumab (Cap+Bev) as first-line therapy followed by cross-over to everolimus plus exemestane (Eve+Exe) as second-line therapy (Arm A) or the reverse sequence (Arm B). The primary endpoint was patients' preference for either regimen, assessed by the Patient Preference Questionnaire 12 weeks after cross-over. Key secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and quality of life (QoL).

show abstract

Section: Discussionmentioning

confidence: 99%

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some studies have shown that pushing patients to assume a more active role than they prefer can have detrimental effects, including increased anxiety and decisional regret . However, in one US study of over 800 breast cancer patients, experiencing a more active role than preferred was associated with improved social and physical well‐being and quality of life . These findings highlight the importance of informing patients about the benefits and risks of participating in TDM, when eliciting their preferred level of involvement.…”

Section: Discussionmentioning

confidence: 99%

“…15 However, in one US study of over 800 breast cancer patients, experiencing a more active role than preferred was associated with improved social and physical well-being and quality of life. 32 These findings highlight the importance of informing patients about the benefits and risks of participating in TDM, when eliciting their preferred level of involvement.…”

Section: Preferred Vs Perceived Involvement In Tdmmentioning

confidence: 92%

Getting the right fit: Convergence between preferred and perceived involvement in treatment decision making among medical oncology outpatients

Mansfield

Bryant

Carey

et al. 2018

Health Science Reports

View full text Add to dashboard Cite

Background and AimsWhile cancer patients' preferences for their level of involvement in treatment decision making (TDM) vary, previous research indicates a large proportion of patients are not experiencing TDM that meets their preferences. Evidence is needed to identify the characteristics of cancer patients who are less likely to report experiencing their preferred level of involvement in TDM, so that appropriate decision‐making support can be provided to them. We examined in a sample of medical oncology outpatients (1) the level of agreement between preferred and perceived involvement in TDM and (2) demographic, psychological, disease, and treatment characteristics associated with having unmet preferences for involvement in TDM.Methods and ResultsCancer patients from three medical oncology treatment centers in Australia completed surveys assessing demographic, disease and treatment variables, psychological distress, and preferred and perceived involvement in TDM. Data were collected between February 2013 and December 2014. Factors associated with having unmet TDM preferences were examined using logistic regression. There were 355 patients included in the analysis (75% response rate). The mean age (±SD) of the participants was 61 (±12), and 45% were male. Overall, 60% of participants reported that their preferences for involvement in TDM were met. No demographic, psychological, disease, or treatment characteristics were significantly associated with an increased probability of not having TDM preferences met.ConclusionsIn line with previous research, a large proportion (40%) of patients reported TDM experiences that were not in alignment with their preferences. Future research should explore additional characteristics that are associated with a lower likelihood of having TDM preferences met.

show abstract

“…Eight sites in seven Midwestern states collaborated in the Share Thoughts on Breast Cancer Study, 10 which was approved by a central Institutional Review Board (IRB) at the University of Iowa. Each study participant provided signed written consent before participating in the study.…”

Section: Study Populationmentioning

confidence: 99%

Factors associated with genetic testing in a cohort of breast cancer survivors

et al. 2019

View full text Add to dashboard Cite

We examined factors associated with self‐reported use of genetic testing among breast cancer survivors based on a 2015 cross‐sectional survey at eight Midwestern sites. Genetic testing was reported in 39% of our 1235 study participants, with higher utilization among those aged <50 and with a triple‐negative cancer. Bilateral mastectomy, having relatives with breast cancer, and younger age were associated with increased genetic testing use. Increasing income, in interaction with age, was associated with use of genetic testing among younger but not older patients. Rural residency emerged as a possible barrier for genetic testing among women with triple‐negative cancer.

show abstract

Preferences and actual chemotherapy decision-making in the greater plains collaborative breast cancer study

Abstract: Patients benefit from providers' efforts to identify patient preferences, encourage an active role in SDM, and tailor decision making to their desired choice.

Cited by 24 publications

References 27 publications

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Getting the right fit: Convergence between preferred and perceived involvement in treatment decision making among medical oncology outpatients

Factors associated with genetic testing in a cohort of breast cancer survivors

Contact Info

Product

Resources

About